Singapore, Oct. 8 -- UK-based Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, and its long-standing partner Celltrion Inc., a South Korea-based biopharmaceutical leader, have signed exclusive licensing agreements across the Middle East and North Africa (MENA) region.

The new agreements will broaden access to cutting-edge and affordable biologics through the introduction of six biosimilar treatments to the region. This also marks a significant advancement in expanding access to biosimilar treatments across key therapeutic areas, including allergic diseases, ophthalmology, skeletal-related disorders, immune diseases and oncology.

By offering high-quality, cost-effective alternatives to complex biologics, Hikma is enab...